Improved chemical strategies for the targeted therapy of cancer

被引：29

作者：

Maison, W

Frangioni, JV

机构：

[1] Univ Hamburg, Inst Organ Chem, D-20146 Hamburg, Germany

[2] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

来源：

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION | 2003年 / 42卷 / 39期

关键词：

antitumor agents; bifunctional linkers; chemical conjugation; peptides; tumor targeting; POTENT; SOMATOSTATIN; CONJUGATE; PEPTIDES; PRODRUGS;

D O I：

10.1002/anie.200301666

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

One of the prerequisites for the successful treatment of cancer is selective or targeted" therapy. Particularly important in this respect are recent advances in the conjugation of cytotoxic compounds to tumor-specific targeting molecules (see picture). The current trend is aimed at minimizing the size of the conjugates."

引用

收藏

页码：4726 / 4728

页数：3

相关论文

共 19 条

[1] A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma [J].

Chan, SY ;

Gordon, AN ;

Coleman, RE ;

Hall, JB ;

Berger, MS ;

Sherman, ML ;

Eten, CB ;

Finkler, NJ .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2003, 52 (04) :243-248

[2] SYNTHESIS OF CONGENERS AND PRODRUGS .3. WATER-SOLUBLE PRODRUGS OF TAXOL WITH POTENT ANTITUMOR-ACTIVITY [J].

DEUTSCH, HM ;

GLINSKI, JA ;

HERNANDEZ, M ;

HAUGWITZ, RD ;

NARAYANAN, VL ;

SUFFNESS, M ;

ZALKOW, LH .

JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (04) :788-792

[3] Monoclonal antibodies in the treatment of malignancy: Basic concepts and recent developments [J].

Dillman, RO .

CANCER INVESTIGATION, 2001, 19 (08) :833-841

[4] Synthesis of target-specific radiolabeled peptides for diagnostic Imaging [J].

Fichna, J ;

Janecka, A .

BIOCONJUGATE CHEMISTRY, 2003, 14 (01) :3-17

[5] A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger [J].

Gopin, A ;

Pessah, N ;

Shamis, M ;

Rader, C ;

Shabat, D .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2003, 42 (03) :327-+

[6]

Gopin A., 2003, ANGEW CHEM INT EDIT, V115, P341

[7]

Guillemard V, 2001, CANCER RES, V61, P694

[8] Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia [J].

Hamann, PR ;

Hinman, LM ;

Hollander, I ;

Beyer, CF ;

Lindh, D ;

Holcomb, R ;

Hallett, W ;

Tsou, HR ;

Upeslacis, J ;

Shochat, D ;

Mountain, A ;

Flowers, DA ;

Bernstein, I .

BIOCONJUGATE CHEMISTRY, 2002, 13 (01) :47-58

[9] Development of methotrexate alpha-peptides as prodrugs for activation by enzyme-monoclonal antibody conjugates [J].

Huennekens, FM .

ADVANCES IN ENZYME REGULATION, VOL 37, 1997, 37 :77-92

[10] HEMODYNAMIC AND TRANSPORT BARRIERS TO THE TREATMENT OF SOLID TUMORS [J].

JAIN, RK .

INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1991, 60 (1-2) :85-100